Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.

[1]  B. Elewski,et al.  Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild‐to‐moderate toenail onychomycosis: results from three randomized studies using double‐blind vehicle‐controlled and open‐label active‐controlled designs , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  J. Szepietowski,et al.  Health-Related Quality of Life in Patients with Nail Disorders , 2011, American journal of clinical dermatology.

[3]  B. Piraccini,et al.  Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. , 2010, Journal of the American Academy of Dermatology.

[4]  Fungal nail infections: diagnosis and management. , 2009, Prescrire international.

[5]  A. Kimball,et al.  New antifungal therapies for the treatment of onychomycosis. , 2009, Expert opinion on investigational drugs.

[6]  B. Sigurgeirsson,et al.  A multicentre, randomized, controlled study of the efficacy, safety and cost‐effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement , 2007, The British journal of dermatology.

[7]  E. Warshaw,et al.  Toenail onychomycosis: current and future treatment options , 2007, Dermatologic therapy.

[8]  E. Baran,et al.  Special paper Advances in the diagnosis and treatment of onychomycosis , 2006 .

[9]  F. Kianifard,et al.  Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. , 2006, The American journal of geriatric pharmacotherapy.

[10]  E. Warshaw,et al.  Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. , 2005, Journal of the American Academy of Dermatology.

[11]  M. Lecha,et al.  Treatment options – development of consensus guidelines , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  R Baran,et al.  Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  H. Maibach,et al.  Progress on New Therapeuties for Fungal Nail Infections , 2005 .

[14]  D. Kobayashi,et al.  In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  D. Lubeck,et al.  Quality of life of persons with onychomycosis , 1993, Quality of Life Research.

[16]  D. Armstrong,et al.  Assessing Treatment Outcomes in Toenail Onychomycosis Clinical Trials , 2004, American journal of clinical dermatology.

[17]  J. Arrese,et al.  Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical Problem , 2003, Dermatology.

[18]  K. Goa,et al.  Terbinafine , 2003, American journal of clinical dermatology.

[19]  K. Kakehi,et al.  Therapeutic Efficacy of Topically Applied KP-103 against Experimental Tinea Unguium in Guinea Pigs in Comparison with Amorolfine and Terbinafine , 2002, Antimicrobial Agents and Chemotherapy.

[20]  S. Murdan.  Drug delivery to the nail following topical application. , 2002, International journal of pharmaceutics.

[21]  W. Joseph,et al.  Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. , 2000, Journal of the American Podiatric Medical Association.

[22]  de CUYPER,et al.  Long‐term outcomes in the treatment of toenail onychomycosis , 1999, The British journal of dermatology.

[23]  D. Patrick,et al.  The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. , 1999, Journal of the American Academy of Dermatology.

[24]  R. Scher.  Onychomycosis: therapeutic update. , 1999, Journal of the American Academy of Dermatology.

[25]  J. Crissey.  Common dermatophyte infections. A simple diagnostic test and current management. , 1998, Postgraduate medicine.

[26]  L. Drake.  Impact of onychomycosis on quality of life. , 1997, Journal of the American Podiatric Medical Association.

[27]  B. Elewski,et al.  Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. , 1997, Archives of dermatology.

[28]  R. Hay,et al.  The impact of onychomycosis on quality of life , 1997, Clincal and Experimental Dermatology.

[29]  B. Lippold,et al.  In‐vitro Permeability of the Human Nail and of a Keratin Membrane from Bovine Hooves: Influence of the Partition Coefficient Octanol/Water and the Water Solubility of Drugs on their Permeability and Maximum Flux , 1997, The Journal of pharmacy and pharmacology.

[30]  R. Scher.  Onychomycosis: a significant medical disorder. , 1996, Journal of the American Academy of Dermatology.